These findings provide new insights into the mechanism by which tumor-derived cytokines regulated cancer progression, consolidate the crosstalk between STAT3 and β-catenin signaling, and raise the possibility that arctigenin acts as an inhibitor of tumor-derived GM-CSF and TSLP for the treatment of breast cancer. This evidence concerns the gene TSLP and breast carcinoma.